8-K: Cocrystal Pharma to Present Positive Norovirus Antiviral Phase 1 Data at Military Health Symposium

Cocrystal Pharma, Inc. announced that its broad-spectrum protease inhibitor CDI-988, a novel norovirus antiviral, will be featured in an oral presentation discussing Phase 1 results at the 2025 Military Health System Research Symposium.

Summary

• Cocrystal Pharma, Inc. (Nasdaq: COCP) will present its broad-spectrum protease inhibitor CDI-988 at the 2025 Military Health System Research Symposium (MHSRS) in Kissimmee, Fla., from August 4-7, 2025.
• Dr. Sam Lee, the Company's President and co-CEO, will deliver an oral presentation on August 4, 2025, discussing Phase 1 results of CDI-988 during the Broad-Spectrum Anti-Viral Countermeasures breakout session.
• CDI-988 is being developed as a norovirus prophylaxis and treatment, targeting the virus's core replication machinery to halt infection regardless of viral strain or mutation.
• The company has completed a single-center, randomized, double-blind, placebo-controlled Phase 1 study in healthy adults, evaluating the safety, tolerability, and pharmacokinetics of CDI-988, including a food effect cohort.
• Norovirus is a leading global cause of acute gastroenteritis, with no approved antiviral agents or vaccines, posing a significant threat in confined spaces like military settings.
• CDI-988 is designed as a broad-spectrum inhibitor to a highly conserved region in the active site of 3CL viral proteases, with potential as a first-in-class oral treatment for both noroviruses and coronaviruses.
• Cocrystal utilizes a proprietary structure-based platform technology, combining structural biology, enzymology, and medicinal chemistry, to develop novel antiviral agents with rapid turnaround of structural information.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful completion of Phase 1 trials for a novel, broad-spectrum antiviral (CDI-988) targeting an unmet medical need (norovirus), and the upcoming presentation at a prestigious military health conference. This indicates significant progress in the drug development pipeline. However, the sentiment is tempered by the explicit mention of the need for additional capital and the inherent risks associated with clinical-stage biotechnology development.

Positives

• CDI-988, a novel norovirus antiviral, has completed Phase 1 clinical trials, indicating progress in its development pipeline.
• The drug will be presented at a prestigious conference, the Military Health System Research Symposium, providing significant visibility and validation.
• CDI-988 is a broad-spectrum protease inhibitor with a novel mechanism of action, targeting the virus's core replication machinery, which could make it effective against various strains and mutations.
• It is being developed for norovirus, a condition with no currently approved antiviral agents or vaccines, indicating a large unmet medical need and market opportunity.
• The drug is also noted to have potential as a first-in-class oral treatment for both noroviruses and coronaviruses, expanding its potential utility.
• Cocrystal's proprietary structure-based platform technology is highlighted as a strength, enabling the development of best-in-class antiviral therapies with desirable characteristics like fast onset and high barrier to resistance.

Risks

• The company needs additional capital to fund its operations over the next 12 months.
• Risks exist relating to the company's ability to obtain regulatory approval for and proceed with clinical trials, including recruiting volunteers and procuring materials.
• The results of clinical studies may not be favorable or as expected.
• There is a risk that the company's and its collaboration partners' technology and software may not perform as expected.
• General risks arising from clinical studies, receipt of regulatory approvals, and regulatory changes could impact development.
• Potential development of effective treatments and/or vaccines by competitors could reduce market opportunity.
• Potential mutations in a targeted virus may result in variants resistant to a product candidate.
• Government actions, such as tariffs, may cause delays or force the company to incur additional costs for development programs.

Future Outlook

Cocrystal Pharma believes CDI-988 could be a breakthrough for norovirus prophylaxis and treatment, potentially transforming how outbreaks are prevented and treated. The company aims to develop best-in-class antiviral therapies that are fast-acting, safe, well-tolerated, easy to administer, effective against all viral subtypes, and have a high barrier to viral resistance using its proprietary structure-based platform technology.

Management Comments

• Dr. Sam Lee, President and co-CEO, stated, "I am pleased to be discussing CDI-988 at this prestigious conference that showcases innovative antiviral agents to treat militarily relevant pathogens."
• Dr. Lee added, "Cocrystal developed CDI-988 as a potential breakthrough for norovirus prophylaxis and treatment using our proprietary structure-based platform technology. Unlike conventional antivirals, it targets the virus core replication machinery, halting infection at early stages regardless of viral strain or mutation."
• Dr. Lee also commented, "We believe CDI-988 could transform how norovirus outbreaks are prevented and treated."

Industry Context

Norovirus is a significant global health concern, being the leading cause of acute gastroenteritis worldwide, with particular relevance in confined environments such as military settings where rapid spread can severely impact operational effectiveness. The absence of approved antiviral agents or vaccines for norovirus highlights a substantial unmet medical need, positioning Cocrystal Pharma's CDI-988 as a potentially groundbreaking solution in this therapeutic area.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess CDI-988 against global industry benchmarks.
• The lack of approved norovirus antivirals or vaccines means CDI-988, if successful, would be a first-in-class treatment, making direct comparisons challenging.

Stakeholder Impact

• Shareholders: Potential positive impact due to advancement of a key drug candidate and increased visibility, but also potential dilution from future capital raises.
• Patients: Potential future benefit from a novel treatment for norovirus and coronaviruses, addressing an unmet medical need.
• Military Personnel: Direct potential benefit as norovirus outbreaks are a significant concern in military settings.
• Employees: Continued employment and potential growth opportunities as the company progresses its pipeline.
• Regulatory Authorities: Will be monitoring the clinical development and data of CDI-988.

Next Steps

• Oral presentation of CDI-988 Phase 1 results by Dr. Sam Lee at the 2025 Military Health System Research Symposium on August 4, 2025.

Key Dates

Recommendation

Keywords

Cocrystal Pharma, CDI-988, Norovirus, Antiviral, Protease Inhibitor, Phase 1 Clinical Trial, Military Health System Research Symposium, MHSRS, Biotechnology, Drug Development, Infectious Disease, Coronavirus, Acute Gastroenteritis